➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
McKesson
Dow
Harvard Business School
AstraZeneca

Last Updated: May 7, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for MEDI4736

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug MEDI4736?

MEDI4736 is an investigational drug.

There have been 297 clinical trials for MEDI4736. The most recent clinical trial was a Phase 2 trial, which was initiated on September 6th 2019.

The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are AstraZeneca, MedImmune LLC, and National Cancer Institute (NCI).

There are forty-five US patents protecting this investigational drug and nine hundred and twenty-one international patents.

Recent Clinical Trials for MEDI4736
TitleSponsorPhase
Olaparib, Durvalumab and UV1 in Relapsed Ovarian CancerArbeitsgemeinschaft Gynaekologische Onkologie AustriaPhase 2
Olaparib, Durvalumab and UV1 in Relapsed Ovarian CancerBelgian Gynaecological Oncology GroupPhase 2
Olaparib, Durvalumab and UV1 in Relapsed Ovarian CancerEuropean Network of Gynaecological Oncological Trial Groups (ENGOT)Phase 2

See all MEDI4736 clinical trials

Clinical Trial Summary for MEDI4736

Top disease conditions for MEDI4736
Top clinical trial sponsors for MEDI4736

See all MEDI4736 clinical trials

US Patents for MEDI4736

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MEDI4736   Get Started for $10 Synergistic combination of immunologic inhibitors for the treatment of cancer The University of Chicago (Chicago, IL)   Get Started for $10
MEDI4736   Get Started for $10 Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy MedImmune Limited (Cambridge, GB)   Get Started for $10
MEDI4736   Get Started for $10 Heterocyclic modulators of lipid synthesis 3-V Biosciences, Inc. (Menlo Park, CA)   Get Started for $10
MEDI4736   Get Started for $10 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer AstraZeneca AB (Sodertalje, SE)   Get Started for $10
MEDI4736   Get Started for $10 Apilimod for use in the treatment of renal cancer LAM Therapeutics, Inc. (Guilford, CT)   Get Started for $10
MEDI4736   Get Started for $10 Anti-B7 H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer MEDIMMUNE, LLC (Gaithersburg, MD)   Get Started for $10
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MEDI4736

Drugname Country Document Number Estimated Expiration Related US Patent
MEDI4736 Canada CA2889182 2032-10-26   Get Started for $10
MEDI4736 European Patent Office EP2911669 2032-10-26   Get Started for $10
MEDI4736 World Intellectual Property Organization (WIPO) WO2014066834 2032-10-26   Get Started for $10
MEDI4736 Australia AU2015276173 2034-06-17   Get Started for $10
MEDI4736 Australia AU2020210207 2034-06-17   Get Started for $10
MEDI4736 Brazil BR112016028964 2034-06-17   Get Started for $10
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Boehringer Ingelheim
AstraZeneca
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.